Cargando…

Effects of interleukin-2 and interferon-alpha A/D treatment on lymphocytes from tumour-bearing mice.

The in vivo antitumour activities of recombinant human interleukin-2 (rHIL-2) and recombinant human hybrid interferon alpha A/D (rIFN-alpha A/D) were tested in relation to adenocarcinoma 755. The tumour growth, following s.c. inoculation of tumour cells, was inhibited to a greater extent in mice tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Ligo, M., Nakajima, Y., Nishikata, K., Hoshi, A.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1989
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246732/
https://www.ncbi.nlm.nih.gov/pubmed/2786729
_version_ 1782150830402568192
author Ligo, M.
Nakajima, Y.
Nishikata, K.
Hoshi, A.
author_facet Ligo, M.
Nakajima, Y.
Nishikata, K.
Hoshi, A.
author_sort Ligo, M.
collection PubMed
description The in vivo antitumour activities of recombinant human interleukin-2 (rHIL-2) and recombinant human hybrid interferon alpha A/D (rIFN-alpha A/D) were tested in relation to adenocarcinoma 755. The tumour growth, following s.c. inoculation of tumour cells, was inhibited to a greater extent in mice treated with the combination of cytokines than in mice treated with either one alone. Pretreatment with these cytokines did not affect the tumour growth. Injection of tumour-bearing mice with a combination of these cytokines resulted in a marked increase in the total number of lymphocytes in the peritoneal cavity. Among them, Lyt-2+/L3T4- and asialo GM1+ cells were markedly enhanced by the combination of cytokines, and the frequencies of these marker cells were closely correlated with the antitumour activity. In tumour-bearing mice, the size of the thymus was decreased while that of the spleen was increased compared to non-tumour-bearing (normal) mice. Treatment with rHIL-2 caused the thymus, spleen and liver to be larger compared to untreated tumour-bearing mice, but when treated with a combination of rHIL-2 and rIFN-alpha A/D these organs were smaller than when rHIL-2 was administered alone. Thymocytes were drastically changed when mice were bearing a tumour or were treated with a cytokine. Especially immature T-cells, Lyt-2+/L3T4+, were drastically decreased in tumour-bearing mice, but were maintained following administration of rHIL-2 or rIFN-alpha A/D. When treated with rHIL-2 plus rIFN-alpha A/D, Lyt-2+/L3T4+ T-cells were decreased while Lyt-2+/L3T4- T-cells were increased. Frequency of immature T-cells, Lyt-2-/L3T4-, was not changed. On the other hand, T-cell subsets of splenocytes were markedly decreased in tumour-bearing mice compared to normal mice, but all the subsets of splenocytes were almost unchanged even when tumour-bearing mice were treated with rHIL-2 plus rIFN-alpha A/D. Thus, injection of rHIL-2 and rIFN-alpha A/D to tumour-bearing mice resulted in induction of Lyt-2+/L3T4- and asialo GM1+ cells in the peritoneal cavity, and the frequencies correlated with the observed antitumour activity in vivo in this murine model. The increase in Lyt-2+/L3T4- T-cells in the peritoneal cavity may be related to changes in the T-cells in thymus.
format Text
id pubmed-2246732
institution National Center for Biotechnology Information
language English
publishDate 1989
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-22467322009-09-10 Effects of interleukin-2 and interferon-alpha A/D treatment on lymphocytes from tumour-bearing mice. Ligo, M. Nakajima, Y. Nishikata, K. Hoshi, A. Br J Cancer Research Article The in vivo antitumour activities of recombinant human interleukin-2 (rHIL-2) and recombinant human hybrid interferon alpha A/D (rIFN-alpha A/D) were tested in relation to adenocarcinoma 755. The tumour growth, following s.c. inoculation of tumour cells, was inhibited to a greater extent in mice treated with the combination of cytokines than in mice treated with either one alone. Pretreatment with these cytokines did not affect the tumour growth. Injection of tumour-bearing mice with a combination of these cytokines resulted in a marked increase in the total number of lymphocytes in the peritoneal cavity. Among them, Lyt-2+/L3T4- and asialo GM1+ cells were markedly enhanced by the combination of cytokines, and the frequencies of these marker cells were closely correlated with the antitumour activity. In tumour-bearing mice, the size of the thymus was decreased while that of the spleen was increased compared to non-tumour-bearing (normal) mice. Treatment with rHIL-2 caused the thymus, spleen and liver to be larger compared to untreated tumour-bearing mice, but when treated with a combination of rHIL-2 and rIFN-alpha A/D these organs were smaller than when rHIL-2 was administered alone. Thymocytes were drastically changed when mice were bearing a tumour or were treated with a cytokine. Especially immature T-cells, Lyt-2+/L3T4+, were drastically decreased in tumour-bearing mice, but were maintained following administration of rHIL-2 or rIFN-alpha A/D. When treated with rHIL-2 plus rIFN-alpha A/D, Lyt-2+/L3T4+ T-cells were decreased while Lyt-2+/L3T4- T-cells were increased. Frequency of immature T-cells, Lyt-2-/L3T4-, was not changed. On the other hand, T-cell subsets of splenocytes were markedly decreased in tumour-bearing mice compared to normal mice, but all the subsets of splenocytes were almost unchanged even when tumour-bearing mice were treated with rHIL-2 plus rIFN-alpha A/D. Thus, injection of rHIL-2 and rIFN-alpha A/D to tumour-bearing mice resulted in induction of Lyt-2+/L3T4- and asialo GM1+ cells in the peritoneal cavity, and the frequencies correlated with the observed antitumour activity in vivo in this murine model. The increase in Lyt-2+/L3T4- T-cells in the peritoneal cavity may be related to changes in the T-cells in thymus. Nature Publishing Group 1989-06 /pmc/articles/PMC2246732/ /pubmed/2786729 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Ligo, M.
Nakajima, Y.
Nishikata, K.
Hoshi, A.
Effects of interleukin-2 and interferon-alpha A/D treatment on lymphocytes from tumour-bearing mice.
title Effects of interleukin-2 and interferon-alpha A/D treatment on lymphocytes from tumour-bearing mice.
title_full Effects of interleukin-2 and interferon-alpha A/D treatment on lymphocytes from tumour-bearing mice.
title_fullStr Effects of interleukin-2 and interferon-alpha A/D treatment on lymphocytes from tumour-bearing mice.
title_full_unstemmed Effects of interleukin-2 and interferon-alpha A/D treatment on lymphocytes from tumour-bearing mice.
title_short Effects of interleukin-2 and interferon-alpha A/D treatment on lymphocytes from tumour-bearing mice.
title_sort effects of interleukin-2 and interferon-alpha a/d treatment on lymphocytes from tumour-bearing mice.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246732/
https://www.ncbi.nlm.nih.gov/pubmed/2786729
work_keys_str_mv AT ligom effectsofinterleukin2andinterferonalphaadtreatmentonlymphocytesfromtumourbearingmice
AT nakajimay effectsofinterleukin2andinterferonalphaadtreatmentonlymphocytesfromtumourbearingmice
AT nishikatak effectsofinterleukin2andinterferonalphaadtreatmentonlymphocytesfromtumourbearingmice
AT hoshia effectsofinterleukin2andinterferonalphaadtreatmentonlymphocytesfromtumourbearingmice